Vaccitech to Present at the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical firm, announced that CEO Bill Enright will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 11:00 AM EDT. A live webcast will be available on the Vaccitech website, with a replay posted afterward. Vaccitech specializes in developing immunotherapeutics and vaccines for infectious diseases and cancer, utilizing innovative platforms like ChAdOx1 and ChAdOx2. The company co-invented a COVID-19 vaccine in collaboration with the University of Oxford, licensed to AstraZeneca.

OXFORD, United Kingdom, June 01, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced that the Company’s Chief Executive Officer, Bill Enright, will be presenting at the Jefferies Virtual Healthcare Conference on Thursday, June 3 at 11:00 AM EDT.

A live webcast of the presentation can be accessed through the Events section of the Vaccitech website. Following the live webcast, a replay will be available at the same location.

About Vaccitech plc
Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company’s proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.

Vaccitech Media contacts:
Katja Stout, Scius Communications (EU)
Direct: +44 (0) 7789435990
Email: katja@sciuscommunications.com

Ryo Imai / Robert Flamm, Ph.D. (US), Burns McClellan, Inc.
212-213-0006 ext. 315 / 364
Email: rimai@burnsmc.com / rflamm@burnsmc.com

Henry Hodge, Vaccitech
Direct: +44 (0) 7533 421 442
Email: henry.hodge@vaccitech.co.uk

FAQ

When is Vaccitech's CEO presenting at the Jefferies Virtual Healthcare Conference?

Vaccitech's CEO, Bill Enright, will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 11:00 AM EDT.

How can I watch the Vaccitech presentation live?

You can access the live webcast of Vaccitech's presentation through the Events section of their website.

What does Vaccitech plc focus on?

Vaccitech plc focuses on the discovery and development of immunotherapeutics and vaccines for infectious diseases and cancer.

What vaccine did Vaccitech co-invent?

Vaccitech co-invented a COVID-19 vaccine in collaboration with the University of Oxford, licensed to AstraZeneca.

What is the stock symbol for Vaccitech?

The stock symbol for Vaccitech is VACC.